Safety and efficacy of weekly pemvidutide versus placebo for metabolic dysfunction-associated steatohepatitis (IMPACT): 24-week results from a multicentre, randomised, double-blind, phase 2b study
Towards unified global action on ultra-processed foods: understanding commercial determinants, countering corporate power, and mobilising a public health response